News
LABP
22.47
+0.76%
0.17
Weekly Report: what happened at LABP last week (0506-0510)?
Weekly Report · 6d ago
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Landos Biopharma, Inc. To AbbVie. Under the terms of the proposed transaction, Landos shareholders will receive $ in cash for each share they own.
Barchart · 05/11 12:29
Landos Biopharma, Inc. Quarterly Report: Financial Statements (Unaudited)
Press release · 05/10 10:22
Landos Biopharma’s Latest Deal Faces Tough Regulatory Gauntlet: HSR Act and FTC Scrutiny May Impose Delays and Costs
TipRanks · 05/10 06:01
LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024
Landos Biopharma reported earnings per share of -$1.43 for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of $1.00. Landos biopharma also reported results for the fourth quarter of 2015.
Investorplace · 05/09 17:53
Landos Biopharma Inc <LABP.OQ> expected to post a loss of 100 cents a share - Earnings Preview
Landos Biopharma Inc expected to post a loss of 100 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 10. Average analyst rating on the shares is "hold" and the median 12-month price target is $12.71.
Reuters · 05/08 13:47
Weekly Report: what happened at LABP last week (0429-0503)?
Weekly Report · 05/06 10:48
Weekly Report: what happened at LABP last week (0422-0426)?
Weekly Report · 04/29 10:53
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie reports first-quarter adjusted EPS of $2.31, down 6.1% Y/Y. The company beat the consensus estimate. First-quarter net revenues reached $12.31 billion, up 0.7%. The immunology portfolio generated $5.37 billion in sales.
Benzinga · 04/26 13:54
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 04/22 16:56
Weekly Report: what happened at LABP last week (0415-0419)?
Weekly Report · 04/22 10:45
Landos Biopharma (LABP) Price Target Increased by 154.20% to 12.96
NASDAQ · 04/17 01:56
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
Barchart · 04/16 14:32
Weekly Report: what happened at LABP last week (0408-0412)?
Weekly Report · 04/15 10:39
Weekly Report: what happened at LABP last week (0401-0405)?
Weekly Report · 04/08 10:42
Landos Biopharma Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 04/01 11:22
Landos Biopharma Price Target Cut to $20.42/Share From $50.00 by HC Wainwright & Co.
Dow Jones · 04/01 11:22
HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42
Benzinga · 04/01 11:12
Weekly Report: what happened at LABP last week (0325-0329)?
Weekly Report · 04/01 10:41
Maintaining Hold Rating on Landos Biopharma Amid Acquisition by AbbVie and Limited Upside Potential
TipRanks · 04/01 10:17
More
Webull provides a variety of real-time LABP stock news. You can receive the latest news about Landos Biopharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LABP
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's disease (CD), that targets NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. It has several preclinical product candidates, including LABP-66, LABP-73 and LABP-69. LABP-73, an oral, small molecule NLRX1 agonist for the potential treatment of asthma and eosinophilic disorders.